financetom
Business
financetom
/
Business
/
US bond manager PIMCO looks abroad as US exceptionalism fades
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US bond manager PIMCO looks abroad as US exceptionalism fades
Apr 1, 2025 7:19 AM

NEW YORK (Reuters) - U.S. bond firm PIMCO said on Tuesday that waning business and consumer confidence under President Donald Trump's policies is eroding the edge U.S. capital markets held over the rest of the world, strengthening the case for investors to diversify globally.

Trump is set to unveil "reciprocal tariffs," aligning U.S. duties with those of other nations on April 2, a move that could deepen a market downturn caused by his economic policies that has already seen U.S. stocks post their most dismal three-month stretch since 2022.

"With both business and consumer confidence declining, the U.S. economic and financial-market exceptionalism of recent years could be fading," PIMCO said in a report written by Tiffany Wilding, an economist, and Andrew Balls, chief investment officer for global fixed income.

"With the U.S. signaling a pullback from some traditional functions ... long-held assumptions about the U.S. as a reliable international leader are being challenged," they said. "These changes may coincide with the twilight of the recent U.S. capital markets' outperformance relative to the rest of the world."

PIMCO expects U.S. protectionist policies will rekindle inflation and lead U.S. economic growth to slow this and next year, while government spending in Europe could improve those countries' economic prospects.

"There is a strong case to diversify away from highly priced U.S. equities into a broader mix of global, high-quality bonds," said the California-based fund manager, which manages nearly $2 trillion in assets.

At the same time, while European fiscal expansion could boost growth, it also makes their bonds less attractive, said PIMCO, which instead favors the UK and Australia for so-called 'duration' - or exposure to bonds that could benefit from cuts in interest rates.

More broadly, PIMCO said it anticipates the beginning of a multi-year phase where fixed income assets - such as corporate and sovereign bonds - may outperform equities.

"In this unusually uncertain macroeconomic environment, it's prudent to prioritize simple, stable investments over trying to predict the unpredictable," it said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Orezone Gold Reports High-Grade Mineralization From North Zone at Bombore Gold Mine
Orezone Gold Reports High-Grade Mineralization From North Zone at Bombore Gold Mine
Jan 27, 2025
06:37 AM EST, 01/27/2025 (MT Newswires) -- Orezone Gold ( ORZCF ) , which gained more than 4% on Friday, late on Sunday posted drilling results with high grades from its flagship Bombore gold mine in Burkina Faso. The results, centered on the North Zone, included 2.55 grams per tonne (g/t) gold over 23 meters, including 5.54 g/t gold over...
Veru's muscle preserving drug meets main goal in mid-stage study
Veru's muscle preserving drug meets main goal in mid-stage study
Jan 27, 2025
Jan 27 (Reuters) - Veru ( VERU ) said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage study. (Reporting by Bhanvi Satija in Bengaluru; Editing by Arun Koyyur) ...
Pfizer's BRAFTOVI Combination Gets FDA Approval, Improves Outcomes in Colorectal Cancer
Pfizer's BRAFTOVI Combination Gets FDA Approval, Improves Outcomes in Colorectal Cancer
Jan 27, 2025
06:30 AM EST, 01/27/2025 (MT Newswires) -- Pfizer ( PFE ) said Saturday that its Phase 3 BREAKWATER study showed a 61% objective response rate for the BRAFTOVI combination therapy in patients with BRAF V600E-mutant metastatic colorectal cancer, compared to 40% for standard chemotherapy, based on an independent review. The BRAFTOVI treatment, which includes cetuximab and mFOLFOX6, has been approved...
Ancora nominates nine candidates to U.S. Steel board, company says
Ancora nominates nine candidates to U.S. Steel board, company says
Jan 27, 2025
(Reuters) - Activist investor Ancora has nominated nine candidates to U.S. Steel's board of directors after reporting a 0.18% stake in the steelmaker, the company said on Monday. On Sunday, the Wall Street Journal reported that Ancora intends to rally shareholders to oust U.S. Steel's CEO David Burritt. It also plans to pressure the company to drop its merger agreement...
Copyright 2023-2026 - www.financetom.com All Rights Reserved